on 26 Jul 2010
Last Applicant/ Owned by
Veracyte, Inc.
6000 Shoreline Court, Suite 300
South San Francisco,, , 94080
Serial Number
UK00909272113 filed on 26th Jul 2010
Registration Number
UK00909272113 registered on
29th May 2015
Correspondent Information
CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place, 78 Cannon St
London,
EC4N 6AF
Scientific research and development services in the fields of oncology, the treatment of cancer and cancer diagnostics; pharmaceutical research in the fields of pharmaceutical preparations used in the diagnosis and treatment of cancer; drug and pharmaceutical discovery; scientific research and development services in the field of oncology and the treatment and diagnosis of cancer and immune diseases; development of pharmaceuticals, biopharmaceutical preparations, vaccines, immunotherapy agents and biologics for others; medical and pharmaceutical research services; creation, updating and hosting of a website providing information in the field of oncology and the diagnosis and treatment of cancer; technical help and support services provided by telephone or electronic mail and relating to diagnostic testing; information and advisory services relating to the aforesaid provided online over the internet or extranets.
Medical diagnostic testing services; information and advisory services relating to cancer diagnostics, oncology, and pharmaceuticals, including such services provided on-line from a computer network or the Internet; testing for diagnostic or treatment purposes; medical services, namely treatment of human diseases and disorders; medical consulting services; human medical and prognostic testing services; providing a database in the field of human diseases, and adapted for the inputting and collection of data and information all for treatment and diagnostic purposes; providing medical information; medical diagnostic, theranostic, prognostic and analysis services; medical diagnostic testing, monitoring and reporting services; medical services, namely, analysis of individualized patient data to aid physicians in determining diagnostic, therapeutic and prognostic objectives for patients; providing a centralized database in the field of molecular diagnostics to allow oncologists to acquire and share molecular tumour profiling information and clinical outcomes within a collaborative, secured environment, all for treatment and diagnostic purposes; information and advisory services relating to the aforesaid provided online over the internet or extranets.
UK00909272113
Word
Individual